SGS Announces Expansion of Biopharmaceutical Testing Capabilities

We are pleased to announce new capacity and capabilities at our center of excellence in Lincolnshire, Illinois, USA.

This expansion adds new instrumentation and expertise to a substantial and well-established facility which currently provides outsourcing services to developers and manufacturers in the pharmaceutical, biopharmaceutical and medical device industries.

Our 60,000 square-foot center of excellence is a state-of-the art facility, delivering microbiology, chemistry and molecular biology analytical services to support clients with both small and large molecule testing. It offers an extensive range of innovative analytical solutions, for every phase of product development.

With this expansion in its biopharmaceutical service portfolio, the Lincolnshire facility now provides early cell bank safety assessment, product characterization, method development/validation, raw material testing and support for final product release.

This expansion builds on our global biopharmaceutical expertise and instrumentation, expanding capacity to support the characterization of a full range of biopharmaceutical therapeutics. These enhancements facilitate analytical testing in both the discovery and commercial stages within a single facility, a unique position within our biopharmaceutical network. This provides delivery of a comprehensive, streamlined, and flexible service model to clients.

This is timely given the fast-growing needs of biopharmaceutical companies seeking to accelerate getting their drugs to market cost-effectively. Within such an environment, it is critical that regulatory guidelines are followed, and compliance is achieved, to ensure the quality and safety of the final product. Such factors are key drivers for companies to outsource their complex and specialized analytical requirements.

“Biologics constitute a high-growth segment of the pharmaceutical market, with sales and development of biologics-based products more than doubling over the last decade in North America,” said Mark Rogers, Global Scientific Director, Health & Nutrition, SGS. “With the addition of scientific expertise and leading instrumentation at our Lincolnshire site, SGS is bolstering its biologics testing capabilities to better meet the growing demand for large molecule drug products that are supporting rapid advancements in novel drug discovery.”

For further information, please contact:

Fulvio Martinez
Director, North America Marketing and Communications
SGS
t: +(281) 714-6765